Prediction of Genitourinary Tract Morbidity After Brachytherapy for Prostate Adenocarcinoma
- Normal tissue complication probability: Does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma. Basu, K. S. Jothy; Bahl, Amit; Subramani, V.; Sharma, D. N.; Rath, G. K.; Julka, P. K. // Journal of Cancer Research & Therapeutics;Apr-Jun2009, Vol. 5 Issue 2, p78
Aim: The main objective of this study was to analyze the radiobiological effect of different treatment strategies on high-risk prostate adenocarcinoma. Materials and Methods: Ten cases of high-risk prostate adenocarcinoma were selected for this dosimetric study. Four different treatment...
- 155-6. THE DILEMMA OVER PSA SCREENING. // Cortlandt Forum;01/25/2001, Vol. 14 Issue 1, p80
Discusses an appropriate screening strategy for prostate-specific antigen (PSA). Controversy surrounding serum PSA testing as a screening tool for prostate cancer; Need for a screening test to identify disease sufficiently early in its course; Clinicians' adoption of a program of annual testing...
- Hypofractionated IMRT Is a Viable Option. // Renal & Urology News;Jan2012, Vol. 11 Issue 1, p11
The article reports on the findings of a study which revealed the viability of hypofractionated intensity modulated radiotherapy (IMRT) as a practical approach to effectively preventing recurrence of intermediate or high-risk prostate cancer (PCa) at five years after treatment.
- Does Testosterone Therapy Increase the Risk of Prostate Cancer? Adrian Dobs // Endocrine Practice;Oct2008, Vol. 14 Issue 7, p904
Objective: To review factors affecting use of testosterone therapy for hypogonadism including the persistent controversial link between testosterone therapy and prostate cancer.Methods: We reviewed studies investigating the relationship between testosterone therapy and prostate cancer...
- Study recommends 4-year screening interval for PCa. Guttman, Cheryl // Urology Times;Nov2003, Vol. 31 Issue 11, p1
Reports on the findings of a medical study recommending at least a four-year interval in prostate cancer screening. Research on the sensitivity of initial screening and cancer rate interval during the initial four-year follow-up period after randomization; Consideration for prognostic factors;...
- Brachytherapy for Prostate Cancer: A Systematic Review. Koukourakis, Georgios; Kelekis, Nikolaos; Armonis, Vassilios; Kouloulias, Vassilios // Advances in Urology;2009, Special section p1
Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. To a great extend due to patient lead advocacy forminimally invasive treatment options,...
- What's New At NEIU? Detweiler, Donna // Business People;Sep2015, Vol. 28 Issue 9, p61
A review is offered for the Northeast Indiana Urology, a prostate cancer treatment center located in Indiana.
- Fitting competing risks with an assumed copula. Escarela, Gabriel; Carri�re, Jacques F. // Statistical Methods in Medical Research;Aug2003, Vol. 12 Issue 4, p333
We propose a fully parametric model for the analysis of competing risks data where the types of failure may not be independent. We show how the dependence between the cause-specific survival times can be modelled with a copula function. Features include: identifiability of the problem;...
- Prostate cancer screening: A refined strategy. Pinkowish, Mary Desmond // Patient Care;11/30/2000, Vol. 34 Issue 22, p9
Compares the efficiency of prostate-specific antigen (PSA) screening strategies for prostate cancer detection; Practice of measuring PSA levels annually beginning at age 50 years; Baseline PSA screening at age 40 and again at age 45 years.